GRCL News and Press, Gracell Biotechnologies Inc. From 02/17/22

Gracell Biotechnologies Doses First Patients in First-in-Human Clinical Trial Evaluating GC012F, its Dual-Targeting FasTCAR-T Therapy, in B-Cell Non-Hodgkin's Lymphoma Candidate dual-targeting B cell maturation antigen (BCMA) and CD19 expands Gracell's FasTCAR autologous, next-d...

Gainers: Tritium DCFC DCFC +82%. US Ecology ECOL +69%. Moving iMage Technologies MITQ +29%. Solid Power (NASDAQ:SLDP) +23%. Kaival Brands Innovations Group (NASDAQ:KAVL) +23%. Doximity DOCS +23%. Gracell Biotechnologies (NASDAQ:GRCL) +20%. Bakkt Holdings (NYSE:BKKT) +20%. ...

SUZHOU, China and PALO ALTO, Calif., Feb. 03, 2022 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the tr...

SUZHOU, China and PALO ALTO, Calif., Jan. 18, 2022 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the tr...

Gracell Biotechnologies Unveils Innovation Center in U.S. PR Newswire SUZHOU, China and PALO ALTO, Calif. , Jan. 12, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell" or the "Company"), a global clinical-stage biopharmaceutical c...

Gracell Biotechnologies Selected for Addition to NASDAQ Biotechnology Index PR Newswire SUZHOU and SHANGHAI, China , and PALO ALTO, Calif. , Dec. 16, 2021 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell" or the "Company"), a global clini...

Gracell Bio stands to benefit from tax credits and marketing exclusivity following receipt of ‘orphan drug’ status for its CAR-T cancer treatment. The global CAR T-cell therapy market is projected to grow from $1.1 billion in sales in 2020 to $21.8 billion by 2031, repre...

Gracell Biotechnologies (NASDAQ:GRCL) rises 37% after members of its senior management team informs the Company of their intention to use their personal funds to purchase the Company's American depositary shares on the open market for an aggregate amount up to a maximum of...

Gainers: Pasithea Therapeutics (NASDAQ:KTTA) +257%, Petros Pharmaceuticals (NASDAQ:PTPI) +73%, Gracell Biotechnologies (NASDAQ:GRCL) +64%, iSpecimen (NASDAQ:ISPC) +43%, Qualigen Therapeutics (NASDAQ:QLGN) +33%. Losers: Longeveron (NASDAQ:LGVN) -36%...

Gracell Biotechnologies Announces Senior Management Team Share Purchase Plan PR Newswire SUZHOU, China and PALO ALTO, Calif. , Nov. 23, 2021 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell" or the "Company"), a global clinical-stage bi...